Mineralys Therapeutics, Inc. $MLYS Shares Bought by Bank of America Corp DE

Key Points

• Bank of America increased its Mineralys Therapeutics stake by 11.5% in the first quarter, adding 113,092 shares to own 1.10 million shares valued at approximately $29.8 million, or 1.33% of the company.
• Institutional investors and hedge funds collectively own 84.46% of MLYS, while insiders have sold 217,313 shares worth about $5.6 million over the past 90 days under pre-arranged trading plans.
• Mineralys’ shares opened at $25.64, with the company reporting a steep second-quarter loss of $2.85 per share versus the $0.55 expected loss. Investors are also watching the December 22, 2026 PDUFA target for its lorundrostat hypertension treatment.

Bank of America Corp DE lifted its position in shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Free Report) by 11.5% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,100,372 shares of the company's stock after acquiring an additional 113,092 shares during the quarter. Bank of America Corp DE owned 1.33% of Mineralys Therapeutics worth $29,809,000 as of its most recent SEC filing.

Other institutional investors have also recently modified their holdings of the company. Navalign LLC acquired a new position in shares of Mineralys Therapeutics during the 4th quarter worth approximately $33,000. KBC Group NV acquired a new stake in Mineralys Therapeutics in the 1st quarter valued at $33,000. Royal Bank of Canada increased its holdings in Mineralys Therapeutics by 262.3% in the 4th quarter. Royal Bank of Canada now owns 1,529 shares of the company's stock worth $56,000 after acquiring an additional 1,107 shares in the last quarter. Caitong International Asset Management Co. Ltd raised its position in Mineralys Therapeutics by 1,845.4% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 2,101 shares of the company's stock worth $76,000 after acquiring an additional 1,993 shares during the period. Finally, Russell Investments Group Ltd. raised its position in Mineralys Therapeutics by 14,091.3% during the third quarter. Russell Investments Group Ltd. now owns 3,264 shares of the company's stock worth $124,000 after acquiring an additional 3,241 shares during the period. 84.46% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Mineralys Therapeutics

In other news, CEO Jon Congleton sold 75,000 shares of the company's stock in a transaction that occurred on Tuesday, June 30th. The shares were sold at an average price of $26.14, for a total value of $1,960,500.00. Following the transaction, the chief executive officer directly owned 614,321 shares in the company, valued at approximately $16,058,350.94. This represents a 10.88% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider David Malcom Rodman sold 2,170 shares of the stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $27.09, for a total transaction of $58,785.30. Following the transaction, the insider directly owned 51,384 shares of the company's stock, valued at $1,391,992.56. The trade was a 4.05% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 217,313 shares of company stock valued at $5,624,488 in the last ninety days. Insiders own 18.94% of the company's stock.

More Mineralys Therapeutics News

Here are the key news stories impacting Mineralys Therapeutics this week:

• Positive Sentiment: Near-term estimates improved: HC Wainwright raised its Q3 2026 EPS estimate to a loss of $0.56 from $0.61 and its Q4 estimate to a loss of $0.60 from $0.70. The firm maintained its Buy rating, indicating continued confidence in Mineralys’ prospects. Mineralys Therapeutics analyst coverage
• Positive Sentiment: Regulatory catalyst remains intact: Mineralys reiterated a December 22, 2026 PDUFA target date for lorundrostat, its investigational hypertension treatment, and said launch preparations are advancing. Approval could provide the company with its first commercial opportunity. Mineralys second-quarter results and corporate update
• Positive Sentiment: Cash runway and leadership support the launch plan: Management said its funding should support operations into 2028, while the appointment of Dr. Terry Ferguson as chief medical officer adds cardiovascular-development expertise ahead of a potential launch.
• Neutral Sentiment: Inducement awards granted to new CMO: Mineralys authorized options covering 135,000 shares and restricted stock units covering 102,400 shares for Dr. Ferguson. The awards help recruit key leadership but could modestly increase future share dilution. Mineralys inducement award announcement
• Negative Sentiment: Large quarterly earnings miss: Mineralys reported a second-quarter loss of $2.85 per share, far worse than the $0.55 consensus loss. The result highlights ongoing pre-commercial cash burn and likely contributes to investor caution.
• Negative Sentiment: Long-term earnings outlook was reduced: HC Wainwright cut its FY2026 EPS forecast to a loss of $4.47 from $2.33, FY2027 to a loss of $3.78 from $2.84, and FY2028 to a loss of $2.27 from $1.52. Its FY2029 profit estimate fell to $0.42 from $0.92, while FY2030 declined to $3.41 from $3.73. These revisions suggest profitability may take longer to develop.
• Negative Sentiment: Insider selling adds a modest negative signal: David Malcom Rodman sold 2,170 shares for approximately $58,785, reducing his stake by 4.05%. The transaction was conducted under a pre-arranged Rule 10b5-1 plan, which limits its signaling value. Mineralys insider sale

Wall Street Analysts Forecast Growth

MLYS has been the subject of a number of research reports. Jefferies Financial Group reissued a "hold" rating on shares of Mineralys Therapeutics in a research note on Monday, June 1st. Zacks Research cut Mineralys Therapeutics from a "hold" rating to a "strong sell" rating in a report on Thursday. Wall Street Zen lowered Mineralys Therapeutics from a "sell" rating to a "strong sell" rating in a research note on Saturday. TD Cowen initiated coverage on Mineralys Therapeutics in a report on Monday, April 27th. They set a "buy" rating for the company. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Mineralys Therapeutics in a research report on Friday, July 17th. Six analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus target price of $49.33.

Mineralys Therapeutics Stock Down 1.7%

NASDAQ MLYS opened at $25.64 on Friday. Mineralys Therapeutics, Inc. has a 52 week low of $14.16 and a 52 week high of $47.65. The company has a quick ratio of 44.33, a current ratio of 34.46 and a debt-to-equity ratio of 0.18. The business's fifty day simple moving average is $26.48 and its 200-day simple moving average is $27.54. The firm has a market cap of $2.27 billion, a PE ratio of -6.05 and a beta of 0.68.

Mineralys Therapeutics (NASDAQ:MLYS - Get Free Report) last posted its earnings results on Wednesday, August 12th. The company reported ($2.85) earnings per share for the quarter, missing the consensus estimate of ($0.55) by ($2.30). As a group, equities analysts anticipate that Mineralys Therapeutics, Inc. will post -4.46 earnings per share for the current year.

About Mineralys Therapeutics

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc and changed its name to Mineralys Therapeutics, Inc in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.

Want to see what other hedge funds are holding MLYS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source